ClinicalTrials.gg
RecruitingNCT02705287Updated Apr 1, 2026

Vitamin D Dynamics in Women

An observational study in Pregnancy, sponsored by Cornell University. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Cornell University · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
20 Years to 39 Years
Sex
Female
01

Study summary

The goal of this project is to utilize stable isotopically labeled vitamin D3 and state of the art mass spectrometric methodology to assess vitamin D dynamics during pregnancy in relation to relation to obesity and vitamin D binding protein genotype. At the conclusion of this study, the investigators will have obtained novel information on the absorption and utilization of vitamin D in women and the degree to which vitamin D utilization during pregnancy is impacted by genetic ancestry, vitamin D binding protein concentration and genotype and by excess adiposity. The long-term goal is to better understand the unique metabolism of vitamin D during pregnancy.

Read the detailed description

Nearly 30% of US women are either vitamin D insufficient or deficient. Vitamin D inadequacy during gestation is increasingly linked to adverse birth outcomes including preterm birth, the risk of cesarean section and placental and pregnancy-associated infections. At this time the Institute of Medicine (IOM) has not advocated any increase in vitamin D intake across gestation but this remains controversial in large part due to insufficient information on the basic physiology of vitamin D. Pregnancy induces dramatic changes in regulation of vitamin D. The investigators hypothesize that increased maternal, placental, and fetal vitamin D requirements during late gestation will result in an increase in vitamin D absorption and a decrease in the half-life of both vitamin D3 and 25-hydroxyvitamin D. The fetus is entirely dependent on maternal vitamin D to meet its requirements for this nutrient. Maternal vitamin D is thought to be passively transferred across the placenta to the fetus given that neonatal concentrations of 25(OH)D are at least 20-30% lower than maternal 25(OH)D concentrations. To date, much of what is known about vitamin D absorption and utilization in humans has been extrapolated from early radiotracer studies in adult men and non-pregnant women and there are no in vivo data to determine if maternal vitamin D3 or maternal 25(OH)D3, or both, can be transferred across the placenta to the fetus

The specific aims of this project are to:

  1. To characterize the impact of pregnancy on the absorption of vitamin D3, conversion into 25(OH)D3, and serum half-life of 25OH)D3 in pregnant and non-pregnant women using tri-deuterated vitamin D3, state of the art UHPLC-MS/MS methodology and mathematical modeling.
  2. To study the impact of obesity on vitamin D kinetics and the D content of serum and adipose tissue in pregnant and non-pregnant women.
  3. To evaluate the impact of genetic ancestry on vitamin D kinetics and the D content of serum and adipose tissue in pregnant and non-pregnant women.
02

Conditions studied

  • Pregnancy

Keywords

  • vitamin D
  • half life
  • kinetics
03

In context

Lead sponsor

Cornell University is the lead sponsor of 103 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women and non-pregnant women of reproductive age

Eligibility criteria

Inclusion Criteria (Non-pregnant and pregnant participants participants):

  • Self-reported White and Black women
  • Age 20-39
  • (BMI) 1or pre-pregnancy BMI (If currently pregnant) either 18.5-24.9 kg/m2 or greater than or equal to 30 kg/m2

Inclusion Criteria (Additional criteria for pregnant participants):

  • Singleton pregnancy
  • Recruited in first trimester, second trimester, or third trimester
  • No pregnancy complications

Exclusion Criteria (Non-pregnant and pregnant participants):

  • BMI or pre-pregnancy BMI \<18.5 kg/m2
  • (HIV) infection
  • Diagnosed eating disorder
  • Malabsorption disease
  • Diabetes
  • Elevated diastolic blood pressure (>110 mm/Hg)
  • use
  • Substance abuse history
  • Current use of medications known to influence vitamin D or calcium homeostasis
  • Plans to travel to lower latitude during the 20-day study period
  • Plans to become pregnant during the study period (non-pregnant only)
  • Refuses to discontinue tanning bed use during study period
  • Refuses to discontinue vitamin or mineral supplement use during study period (non-pregnant only)

Exclusion Criteria (Additional criteria for pregnant participants):

  • Gestational diabetes
  • Pregnancy hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Vitamin D dynamics- pregnant

    Pregnant women recruited to measure Vitamin D dynamics during pregnancy.

    Other: Vitamin D dynamics-pregnant

  • Vitamin D dynamics-nonpregnant

    Non-pregnant women recruited to measure Vitamin D dynamics.

    Other: Vitamin D dynamics-nonpregnant

Interventions

  • OtherVitamin D dynamics-pregnant

    tracer dose of deuterated vitamin D3

  • OtherVitamin D dynamics-nonpregnant

    tracer dose of deuterated vitamin D3

06

What researchers measure

Primary outcomes

  1. Impact of pregnancy on serum vitamin D absorption

    A baseline blood sample (20 mL) will be obtained for analysis of the baseline concentrations of indicators of vitamin D status. Each woman will be asked to ingest two pieces of toast onto which a dose of 35 μg of \[6,19,19-d3\]-vitamin D3 has been added. Women will return to the at 4 hour, 8 hour, Day 2, 10, 25, and 40 (± 2 days) for an additional blood sample (15 mL each) to assess the disappearance of the tri-deuterated D3, conversion into 25(OH)D3, and serum half-life of 25(OH)D3.

    Time frame: Across 40 days study period

  2. Impact of obesity on vitamin D absorption

    A baseline blood sample (20 mL) will be obtained for analysis of the baseline concentrations of indicators of vitamin D status. Each woman will be asked to ingest two pieces of toast onto which a dose of 35 μg of \[6,19,19-d3\]-vitamin D3 has been added. Women will return to the at 4 hour, 8 hour, Day 2, 10, 25, and 40 (± 2 days) for an additional blood sample (15 mL each) to assess the disappearance of the tri-deuterated D3, conversion into 25(OH)D3, and serum half-life of 25(OH)D3. Body composition measure using Bioelectrical Impedance Analysis (BIA) will be conducted on Day 0 for all participants and Day 40 for he pregnant participants to obtain information on BMI and fat mass. Adipose tissue (\<1 gram) will be extracted using needle biopsy from the upper buttock area on all participants for D content analysis.

    Time frame: Across 40 days study period

  3. Impact of ancestry on serum vitamin D absorption

    A baseline blood sample (20 mL) will be obtained for analysis of the baseline concentrations of calcitropic hormones and indicators of vitamin D status. Each woman will be asked to ingest one quarter piece of toast onto which a dose of 35 ug of \[6,19,19-d3\]-vitamin D3 has been added. Women will return to the at 4 hour, 8 hour, Day 1, 3, 10, 25, and 40 (± 2 days) for an additional blood sample (15 mL each) to assess the disappearance of the tri-deuterated D3, conversion into 25(OH)D3, and serum half-life of 25(OH)D3. DNA will be extracted to perform ancestry genotyping and determine vitamin D binding protein genotypes.

    Time frame: Across 40 days study period

Secondary outcomes

  1. Placental protein quantification

    At delivery placental tissue will be collected for evaluation of placental mRNA expression and protein abundance of CYP2R1, CYP24A1 and CYP27B1 following methods we, and others have published. This will help us obtain data on placental contributions to D utilization to inform our mathematical model and hypotheses.

    Time frame: Across 40 days study period

07

Study locations

1 of 1 sites recruiting
  • University of Rochester, 518 Hylan Building
    Rochester, New York 14627, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for May 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2016
First posted
Mar 10, 2016
StartActual
Oct 28, 2024
Primary completionEst.
May 2028
CompletionEst.
May 2029
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02705287
Lead sponsor
Cornell University
Responsible party
Sponsor
First posted
Mar 10, 2016
Start date
Oct 28, 2024
Primary completion
May 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Apr 1, 2026

Study contacts

Kimberly O. O'Brien, PhD
Contact
koo4@cornell.edu
607-255-3743
Kimberly O. O'Brien, PhD
principal investigator · Cornell University
Eva Pressman, MD
principal investigator · University of Rochester

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion